Chronic administration of D-amphetamine increases [3H]spiroperidol binding in cat brain

Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

RATIONALE

Human behavioral pharmacology studies can examine how medications that target different neurotransmitter systems influence different aspects of smoking. Naltrexone and bupropion have been shown to alter ad lib smoking behavior; however, medication effects on nicotine reward in a cigarette choice paradigm have yet to be investigated.

OBJECTIVE

This study explored the effects of an acute dose of naltrexone, bupropion, or placebo on the relative reinforcing value of nicotine from cigarette smoking using new nicotine and de-nicotinized (Quest, 0.6 and 0.05 mg = "denicotinized") cigarettes.

METHODS

In a double-blind, within-subjects design, 26 dependent smokers participated in three experimental cigarette smoking sessions following pretreatment with either naltrexone (50 mg), bupropion (300 mg), or placebo. After medication administration and 2 h of monitored deprivation from cigarettes and food, participants rated their responses to the initial exposure to the cigarettes and then participated in four choice sessions over a 2-h period during which they could take four puffs from either cigarette.

RESULTS

The relative reinforcing value of nicotine, as measured by the number of nicotine puffs chosen out of 16, was significantly lower following naltrexone compared to placebo. There were no effects of an acute dose of bupropion on nicotine choices.

CONCLUSIONS

These results suggest that naltrexone may reduce the relative reinforcing effects of nicotine via cigarette smoking and support ongoing investigation of opioid antagonists as potential smoking cessation pharmacotherapies.

D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment

BACKGROUND

Animal and postmortem studies indicate that neuroleptic therapy may induce D2 dopamine receptor up-regulation in the basal ganglia.

METHODS

To address this phenomenon in a clinical study, we investigated the D2 dopamine receptor binding in 15 DSM-III-R schizophrenics in the drug-naive state and 3 days after completion of a standardized neuroleptic therapy (benperidol 12-16 mg/day, for 25 days) using single photon emission computed tomography (SPECT). SPECT scans were obtained 2 hours after intravenous injection of 185 MBq 123I-iodobenzamide. For analysis, basal ganglia to frontal cortex (BG/FC) ratios were calculated and the patient sample was subgrouped into patients with a favorable versus a poor treatment response.

RESULTS

Neuroleptic treatment led to decreased BG/FC ratios in patients with a favorable response, but increased ratios in the poor responders (df = 1, F = 4.1, p = .06). Changes of BG/FC ratios were significantly correlated with extrapyramidal side effects but not with neurological soft signs.

CONCLUSIONS

Our findings suggest that neuroleptic therapy may induce D2 dopamine receptor up-regulation in a subgroup of patients characterized by poor treatment response and pronounced extrapyramidal side effects.

[123I]IBZM SPET analysis of dopamine D2 receptor occupancy in narcoleptic patients in the course of treatment

Elevated levels of central D2 dopamine receptors were found on postmortem examination in cases of human narcolepsy. In vivo investigations using positron emission tomography (PET) and single photon emission tomography (SPET) found no changes of D2 binding in the striatal structures. To investigate whether the elevated D2 receptors in postmortem investigations are due to long-term treatment effects, we applied 123I-labeled (S)-2-hydroxy-3-iodo-6-methoxy-([1-ethyl-2-pyrrolidinyl]methyl) benzamide (IBZM) ([123I]IBZM, a highly selective CNS D2 dopamine receptor ligand) and SPET in narcoleptic patients in the course of treatment with stimulants and/or antidepressants. Before treatment we found no changes in D2 binding in 10 patients (in comparison to 10 normal controls). After treatment (performed in five patients for 3 months) we found changes in D2 binding in four of them, indicating that the results of the postmortem studies could have been influenced by long-term medications. Human narcolepsy seems not to be related to a striatal D2 dopaminergic disturbance.

Dopamine D2-receptors in human narcolepsy: a SPECT study with 123I-IBZM

Increased dopamine D2 receptor binding in basal ganglia has been reported in human narcolepsy. These studies have been based on post-mortem material of 8 patients, most of them also medicated for narcolepsy. We studied six narcoleptics without stimulant or anticataplectic medication. The patients had an unambiguous history of cataplexy, and they were also studied polygraphically. Single photon emission computed tomography (SPECT) imaging was performed. The D2 receptor density was determined by using 123I-iodobenzamide (IBZM). The control subjects were 8 unmedicated Parkinson patients with one-sided (hemiparkinsonian) clinical symptoms. The D2 receptor density in them is known to be normal or somewhat increased compared to healthy normals. The striatum/frontal D2 activity ratio was 1.331 +/- 0.084 (with phantom study correction 2.101 +/- 0.300) in the narcoleptic patients, and in the parkinsonian controls 1.321 +/- 0.052 (2.067 +/- 0.185) for the asymptomatic side and 1.335 +/- 0.025 (2.117 +/- 0.090) for the symptomatic side (i.e. contralateral to the side with the clinical extrapyramidal signs). There was no statistical difference between the groups or between the symptomatic and asymptomatic side in the Parkinson patients. Thus, our results differ from the earlier post-mortem studies.

Changes in dopamine-dependent electrochemical signal in the nucleus accumbens associated with repeated cocaine injections in rats

High-speed chronoamperometry with Nafion-coated monoamine-sensitive electrodes was used to evaluate changes in the extracellular dopamine (DA) concentrations in the nucleus accumbens following each of a series of daily cocaine injections (15 mg/kg, i.p.; 5 days and challenge 3-4 days later) in freely moving rats. The first drug injection caused triphasic changes in the DA-dependent electrochemical signal. An initial transitory decrease in signal (equivalent of -45 nM DA) was followed by a slow increase (from 16 to 100 min; +155 nM) than a subsequent long-term and profound decrease (2-4 h; -100 to 200 nM). Subsequent daily injections did not cause an initial decrease; immediately after cocaine injection the signal increased rapidly to reach a peak of approximately 150-200 nM. The initial component of this signal increase (2-6 min) was more powerful with repeated daily injections, while the amplitude and duration of the signal increase were similar. Similar changes in locomotion were seen following repeated cocaine injections: movement activation occurred with shorter latency and reached a peak earlier, but total amount of counts was relatively stable. The gradual enhancement of the initial components of the electrochemical signal increase following repeated drug injections suggests that the mechanisms of conditioning contribute to the changes of mesolimbic DA accompanying development of cocaine sensitization.

Autoradiographic studies of post-mortem human narcoleptic brain

Although the pathological basis for narcolepsy is unknown, studies of human and canine narcolepsy have suggested that monoamine and cholinergic metabolism may be altered. We used quantitative autoradiography to assess binding of dopaminergic, noradrenergic, and cholinergic ligands to basal ganglia and amygdala of five narcoleptic and 17 control human brains. Dopamine receptor studies revealed significant increases in D-1 and D-2 receptor binding in the caudate nucleus, as well as large but not significant increases of D-1 binding in the medial globus pallidus, and D-2 binding in the lateral globus pallidus and the lateral nucleus of the amygdala. Alpha-adrenergic receptor studies revealed a significant increase in alpha-2 receptor binding in the putamen and large but not significant increases of alpha-2 binding in the caudate nucleus, and basal and lateral nuclei of the amygdala. Alpha-1 receptor binding was decreased in several areas but the changes were not statistically significant. Studies of two narcoleptic brains revealed small but not statistically significant increases in muscarinic receptor binding in the caudate nucleus, putamen, and amygdala. Although we cannot exclude the possibility that stimulant medications used before death may be partly responsible for these findings, the results suggest that human narcolepsy is associated with upregulation of dopamine and alpha-2 adrenergic receptors in specific brain regions.

Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission

The effects of acute and repeated amphetamine administration on mesolimbic dopamine (DA) neurons was assessed by studying DA and cholecystokinin (CCK) release in the nucleus accumbens (Acc), as well as effects on mRNA genes regulating DA and CCK synthesis in ventral tegmental area (VTA) cells in rats. Amphetamine (1.5 mg/kg) markedly increased extracellular levels of DA in the medial Acc (assessed by in vivo microdialysis) in drug-naive animals, about twice the amount released in animals repeatedly administered the drug for the previous 7 days (twice daily). CCK overflow was found to mirror the DA responses in that the very transient elevation of CCK monitored in drug-naive animals was attenuated in those with prior amphetamine use. The attenuation of both DA and CCK overflow in the medial Acc was found to be associated with a decrease in the number of CCK mRNA-positive VTA neurons (assessed by in situ hybridization histochemistry). Although the number of cells expressing CCK mRNA were decreased, the gene expression in those positive CCK and tyrosine hydroxylase mRNA cells in the VTA was significantly increased. The CCK mRNA neurons in the VTA were positively identified as those projecting to the medial Acc by the local perfusion of Fluoro-gold retrograde tracer via microdialysis probes located in the Acc.

Time-dependent changes in the sensitivity of dopamine neurons to low doses of apomorphine following amphetamine infusion

Changes in dopamine autoregulatory mechanisms following a chronic infusion of amphetamine were studied. Rats were infused with D-amphetamine (4.8 mg/day) for 7 days by osmotic minipumps, and were studied at various times after withdrawal. In contrast to no changes in the spontaneous firing rate of single dopamine cells, the potency of apomorphine in the substantia nigra was markedly decreased soon after withdrawal, followed by an increase 7 days later. The ventral tegmental area showed no changes in either spontaneous firing rate or sensitivity to apomorphine following a 7-day withdrawal. Moderate decreases in striatal and tubercle dopamine concentrations were not accompanied by any significant decrease in basal dopamine synthesis. Under intact impulse-flow, the sensitivity of terminal dopamine synthesis to low doses of apomorphine was decreased immediately following withdrawal; by Day 7 supersensitivity was observed. Direct assessment of terminal autoreceptors following a 7-day withdrawal revealed normo- and supersensitivity of these receptors in the striatum and olfactory tubercle, respectively. Possible mediating mechanisms as well as implications of these findings for the development of characteristic behavioral syndromes during and after amphetamine infusion are discussed.

Neurophysiology and neurochemistry of drug dependence: a review

To understand the neurophysiological and neurochemical mechanisms of drug dependence, the functional significance of dopamine, noradrenaline and endogenous opioid peptides in the mediation of natural, self-stimulation and pharmacological reinforcement are discussed. Data on search of system(s), mediator(s) and neurons of reinforcement as well as my own notions on reinforcement as a critical element in organization and regulation of the organism's adaptive activity in variable environments are presented. The role of chronic drug-induced stable modification of central neurochemical systems' functioning as a basis for the alteration of endogenous reinforcement processes and raising drug dependence are examined in detail for main addictive drugs, opiates and psychomotor stimulants.

Failure of subchronic lisuride to modify A10 dopamine autoreceptors' sensitivity

The concept that prolonged treatment with dopamine (DA) mimetics results in a subsensitivity of DA autoreceptors generally is accepted. However, the present study indicates that the administration of a rather specific DA-D2 agonist, lisuride hydrogen maleate (LIS), for one week (200 micrograms/kg/daily) failed to modify the sensitivity of DA autoreceptors of A10 neurons. Indeed, by using extracellular single unit recording in chloral hydrate-anesthetized rats, we observed that neither intravenous apomorphine nor microiontophoresis of DA changed their firing rate-depressant potency when it was estimated at 1 or 3 days after the last LIS injection. A possible interpretation of the results is that the subchronic stimulation of DA-D2 receptors activates an unknown compensatory mechanism which avoids the changes in their sensitivity. Alternatively, the possibility that LIS may also possess antagonistic properties for DA receptors, which might balance the D2 receptors activation, is discussed.